Abstract
This work explores plant-based strategies for the sustainable production of proteinatious pharmaceuticals and other high-value proteins, using transient and stable transformation. The first approach focuses on engineering safe-to-eat plants free from various bacterial pathogens via introducing genes encoding antibacterial proteins, such as colicin M. The second strategy substitutes plant sources to produce unique proteins in climate-resilient crops, exemplified by the thaumatin II, a natural low-calorie sweetener protein. Finally, the usage of plants as green bioreactors for the pharmaceuticals production, such as human interferon α2b, an essential medicine for antiviral and anticancer treatments.